A Phase II Study of the safety, tolerability and antitumor activity of tucatinib in combination with eribulin and trastuzumab in patients with pretreated unresectable locally advanced or metastatic HER2+ breast cancer

Is this Study for You?

Let's Get Started!




Outpatient CTRC
University of Colorado Hospital

Principal Investigator
Photograph of Elena Shagisultanova

Elena Shagisultanova

Study ID

Protocol Number: 22-1407

More information available at ClinicalTrials.gov: NCT05458674

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers